AMRX - Amneal Pharma gets FDA nod for leuprolide acetate injection to treat prostate cancer
- Amneal Pharmaceuticals ( NYSE: AMRX ) on Wednesday said it had received an abbreviated new drug application approval from the U.S. FDA for its leuprolide acetate injection to treat prostate cancer.
- AMRX expects to launch eight new injectables in 2022, the company said in a statement .
- AMRX said, according to IQVIA, U.S. annual sales for this product for the 12 months ended Sept. 2022 were $81M.
- Amneal ( AMRX ) stock closed +5.9% at $2.33 on Tuesday. Shares were down 1.3% to $2.30 in premarket trading.
For further details see:
Amneal Pharma gets FDA nod for leuprolide acetate injection to treat prostate cancer